-
CSBTA Pharmacokinetics in MASH: Key Findings
2026-09-26
This study integrates plasma pharmacokinetics, tissue distribution, cellular transport, metabolism, and PXR-related regulation to examine how HFHCD-associated MASH changes exposure to three Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated dosing can increase systemic and hepatic exposure, highlighting the need to account for disease-related pharmacokinetic variability when evaluating CSBTA treatment.
-
Angiotensin 1/2 (5-7): Designing Better Assays
2026-09-25
Angiotensin 1/2 (5-7) is a short renin-angiotensin system peptide with research relevance beyond conventional blood pressure studies. This guide focuses on how to design and interpret assays that distinguish peptide-dependent binding effects from receptor activation or viral infection.
-
Bestatin Hydrochloride: Mechanism & Research Use
2026-09-25
Bestatin hydrochloride, also known as Ubenimex, inhibits aminopeptidase activity and supports studies of enzyme-dependent signaling and angiogenesis inhibition. Its effects are model-dependent: a rat neuronal study found that it enhanced angiotensin-evoked activity, while cancer and angiogenesis applications require separate assay validation.
-
Lisinopril Dihydrate in ACE Inhibitor Research
2026-09-24
Use Lisinopril dihydrate to probe ACE-dependent signaling in hypertension, cardiac, and renal research—with assay controls that help separate ACE inhibition from other peptidase effects. This practical guide covers solution preparation, experimental workflows, disease-model readouts, and troubleshooting, while distinguishing product specifications from suggested starting conditions.
-
Angiotensin 1/2 (1-6): Designing Better Binding Assays
2026-09-24
Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, offers a useful probe for studying how angiotensin fragments influence molecular binding. This article translates recent spike–receptor findings into practical assay-design principles while distinguishing biochemical evidence from physiological or clinical conclusions.
-
Sulfo-NHS-LC-Biotin: Practical Labeling Guide
2026-09-23
Sulfo-NHS-LC-Biotin labels accessible primary amines on proteins and peptides for stable detection, capture, or immobilization, including cell-surface protein biotinylation. It is suited to aqueous workflows that need irreversible labeling, but not to intracellular labeling or experiments requiring a reversible tag.
-
JAK Inhibitors and Endothelial Vascular Effects
2026-09-23
A 2025 comparative study shows that approved JAK inhibitors consistently reduce cytokine-induced endothelial IL-6, but differ in their effects on IL-8, adhesion molecules, coagulation factors, and apoptosis. The findings indicate that anti-inflammatory activity alone cannot define vascular safety and provide a practical framework for interpreting JAK inhibitor responses in inflammatory disease models.
-
Lenalidomide and DOT1L: Rewiring Myeloma Immunity
2026-09-22
Lenalidomide (CC-5013) is best understood not only as an immunomodulatory drug, but as a translational platform whose activity can be intensified by epigenetic control of innate immune signaling. This thought-leadership article connects DOT1L biology, assay design, biomarker strategy, and product selection for more rigorous multiple myeloma research.
-
Sex Differences in Angiotensin II Hypertension
2026-09-21
Xue, Pamidimukkala, and Hay used telemetry in conscious, freely moving mice to show that chronic angiotensin II produces a much larger blood-pressure increase in males than females despite similar baseline pressure. Gonadectomy, baroreflex testing, and ganglionic blockade linked this divergence to sex-dependent hormonal and sympathetic regulation, providing a useful framework for interpreting vascular and autonomic mechanisms in hypertension.
-
Arrb2–6-ketoLCA Signaling in Hepatic IRI
2026-09-21
The reference study identifies a hepatocyte Arrb2–6-ketoLCA axis that promotes M2 macrophage polarization and reduces hepatic ischemia–reperfusion injury. Its combination of clinical-sample analysis, hepatocyte-focused mouse genetics, hypoxia–reoxygenation experiments, and metabolomics provides a mechanistic framework for studying hepatocyte–macrophage communication, while leaving adrenergic drug modulation as a separate research question.
-
E-64d for Reliable Cell-Death Assays
2026-09-20
Learn how E-64d (SKU A1903) can improve interpretation of cell viability, proliferation, apoptosis, and cytotoxicity experiments by targeting intracellular cysteine proteases. This scenario-based guide covers mechanism, assay compatibility, preparation, data interpretation, and practical supplier selection.
-
Bradykinin BA5201: Practical Assay Guidance
2026-09-19
This guide explains how to handle Bradykinin (SKU BA5201) as an endothelium-dependent vasodilator peptide in vascular, permeability, smooth muscle, pain, and inflammation workflows. It focuses on product-controlled storage and fresh-solution handling; it does not establish clinical efficacy, diagnostic use, or a universal assay concentration.
-
Lenalidomide (CC-5013): A Causal Assay Framework
2026-09-18
Lenalidomide (CC-5013) is an immune system activation agent and angiogenesis inhibitor with applications across hematologic cancer models. This article presents a causal assay framework linking its established biology to new DOT1L–innate immune findings in multiple myeloma research.
-
Angiotensin (1-7): Reliable Cell Assay Workflows
2026-09-18
A scenario-based guide to using Angiotensin (1-7), SKU A1041, in viability, proliferation, cytotoxicity, and signaling experiments. It connects Mas receptor biology with practical decisions about solvent compatibility, dose selection, assay interpretation, and reagent quality control.
-
Mubritinib (TAK 165): Designing Better Cancer Assays
2026-09-17
Mubritinib (TAK 165) is best understood as a context-dependent mitochondrial complex I inhibitor rather than simply a historical HER2 agent. This guide connects its AML and PEL biology with pH-aware assay design, showing how translational researchers can improve dosing logic, controls, and interpretation.